摘要
目的研究噻托溴铵(思利华)联用沙美特罗替卡松粉吸入剂(舒利迭50/500)治疗重度至极重度慢性阻塞性肺疾病(COPD)患者的疗效及安全性。方法 63名确诊为稳定期的重度至极重度COPD患者随机分为两组:治疗组33例,对照组30例,分别使用思利华+舒利迭(50/500)及思利华+舒利迭(50/250)治疗。在治疗前、治疗1月、6月后行肺功能检测;同期采用6min步行距离评价运动能力,圣乔治呼吸问题调查问卷(SGRQ)评价生活质量。结果两组COPD患者经治疗后肺功能、运动能力、生活质量评分均有明显改善(P<0.01),而思利华及舒利迭(50/500)联合治疗其改善作用更为显著(P<0.01)。其次,在减少加重病例、延缓病情发展的比较中,思利华+舒利迭(50/500)治疗明显优于思利华+舒利迭(50/250)治疗(P<0.01)。结论重度至极重度COPD患者使用思利华+舒利迭(50/500)综合治疗效果要优于思利华+舒利迭(50/250),值得临床推广应用。
Objective To explore the curative effect and safety of tiotropium bromide combined with salmeterol xinafoate and fluticasone propionate（seretide 50/500） in treating the patients with severe to profound chronic obstructive pulmonary disease（COPD）.Methods 63 cases with final diagnosis of severe to profound COPD at stable phase were randomly divided into 2 groups： treatment group（n=33） and control group（n=30）;tiotropium ＋ seretide（50/500） were applied to patients in treatment group while tiotropium ＋ seretide（50/250） were applied to patients in control group;pulmonary function examination was made respectively before treatment,1 month and 6 months after treatment while kinetism was evaluated with 6min walking distance（6-MWD）,and the quality of living was evaluated with St.George＇s Respiratory Questionnaire（SGRQ）.Results After treatment,the pulmonary function,kinetism and the scores of the quality of living in patients of both groups were obviously improved（P〈0.01）,the improvement in treatment group was greater（P〈0.01）;the treatment in treatment group was much superior to that in control group in decreasing aggravated cases and delaying the process of the disease（P〈0.01）.Conclusions The combined treatment of tiotropium ＋ seretide（50/500） is of better curative effect than that of tiotropium ＋ seretide（50/250） for severe to profound COPD.
出处
《西南军医》
2011年第6期976-979,共4页
Journal of Military Surgeon in Southwest China
